Phase II trial of GLYX 13 (Naurex) shows positive results in patients with Depression

Phase IIa results show that a single administration of anti-depressant GLYX 13, from Naurex, produced statistically significant reductions in Depression scores in subjects who had failed treatment with one or more antidepressant agents. The reductions were evident within 24 hours and persisted for an average of seven days. Importantly, the effect size, a measure of the magnitude of the drug's antidepressant efficacy, observed at 24 hours and at seven days after a single administration of GLYX 13, was nearly double the effect size seen with most other antidepressant drugs after 4-6 weeks of repeated dosing.

Ttrial, GLYX 13 was well tolerated. Reported side effects were mild to moderate and were consistent with those observed in subjects receiving placebo. Consistent with previous studies, GLYX 13 did not produce any of the schizophrenia-like psychotomimetic effects associated with other drugs that modulate the NMDA receptor. Rsults are being presented at the 51st Annual Meeting of the American College of Neuropsychopharmacology.